MDT

96.73

-0.29%↓

147.9

+0.78%↑

VEEV

223.62

-2.76%↓

HQY

85.81

+2.85%↑

NEOG

9.25

+1.43%↑

MDT

96.73

-0.29%↓

147.9

+0.78%↑

VEEV

223.62

-2.76%↓

HQY

85.81

+2.85%↑

NEOG

9.25

+1.43%↑

MDT

96.73

-0.29%↓

147.9

+0.78%↑

VEEV

223.62

-2.76%↓

HQY

85.81

+2.85%↑

NEOG

9.25

+1.43%↑

MDT

96.73

-0.29%↓

147.9

+0.78%↑

VEEV

223.62

-2.76%↓

HQY

85.81

+2.85%↑

NEOG

9.25

+1.43%↑

MDT

96.73

-0.29%↓

147.9

+0.78%↑

VEEV

223.62

-2.76%↓

HQY

85.81

+2.85%↑

NEOG

9.25

+1.43%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.06 0.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.02

Max

1.07

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+333.64% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-9.2M 117M
Eelmine avamishind	0.11
Eelmine sulgemishind	1.06

Uudiste sentiment

By Acuity

50%

183 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. jaan 2026, 19:05 UTC

Suurimad hinnamuutused turgudel

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. jaan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. jaan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. jaan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. jaan 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. jaan 2026, 23:10 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. jaan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. jaan 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. jaan 2026, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. jaan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. jaan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. jaan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. jaan 2026, 19:03 UTC

Tulu

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. jaan 2026, 18:50 UTC

Tulu

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. jaan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. jaan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. jaan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. jaan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

333.64% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 333.64%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

183 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.